What did @beingmarcellahill actually say?
She's been on testosterone pellets for two and a half years and says they "literally changed my life" by restoring libido, eliminating joint pain, and stopping the itching she associates with low testosterone. Three weeks into switching to twice-weekly injections, those symptoms are returning. She attributes itchy legs, itchy ears, aching knees and hips, and zero libido to low testosterone levels during the injection transition. She also notes she dislikes the slow draw of oil-based testosterone through a syringe.
She's not making a medical recommendation here. She's documenting a personal experience, which is worth acknowledging before picking it apart. But personal experience has a way of becoming gospel on TikTok, so let's look at what she's actually claiming and whether it holds up.
Does the science back this up?
The symptom rebound is real, but her explanation for why it's happening is incomplete. Pellets release testosterone steadily over 90 days. Injections create peaks and troughs. At three weeks, she may genuinely be experiencing low testosterone, but the picture is more complicated than she's letting on.
A 2021 review by Finkle et al. in the Journal of Clinical Endocrinology and Metabolism documented that subcutaneous pellets produce more stable serum testosterone levels compared to intramuscular injections, which show pronounced peaks 24-72 hours post-injection followed by decline. Her twice-weekly injection schedule actually mimics what many clinicians use to reduce those troughs, so the timing of her symptoms may point to her dose being too low rather than injections being inherently inferior.
The itching claim is where things get shakier. She and her husband are treating leg and ear itching as a reliable low-testosterone symptom. The evidence for that specific symptom as a testosterone deficiency marker in women is thin. Pruritus (itching) can have dozens of causes, and while estrogen shifts in perimenopause can cause skin dryness, testosterone deficiency as a direct driver of itching is not well-established in peer-reviewed literature.
What did they get wrong (or right)?
She got the delivery mechanism basically right. Pellets do dissolve slowly over roughly 90 days, producing relatively stable levels. That part is accurate. The clinical downside she glosses over is that pellet dosing is difficult to reverse if you have a bad reaction, a real limitation that has been flagged in clinical literature.
She got the pellet gym restriction right too. The insertion site requires activity limitations for several days to prevent pellet extrusion, which is a documented complication in studies like Glaser et al. (2013) in Maturitas. That's a legitimate quality-of-life consideration.
What she got wrong, or at least oversimplified, is using itchy legs as a confident testosterone-level readout. That's her husband's lay interpretation, not clinical assessment. Testosterone levels should be measured with serum labs, not scratch patterns. She hasn't mentioned getting bloodwork to confirm she's actually low, which would be the appropriate first step before assuming the injection protocol is failing.
What should you actually know?
If you're considering switching delivery methods, a few things matter that this video doesn't cover. First, three weeks is genuinely early to judge an injection protocol. Serum testosterone from prior pellets can persist for weeks after implantation ends, so her timeline for symptom return may not correlate cleanly with when her pellet levels dropped off.
Second, twice-weekly injections are considered by many endocrinologists to be a reasonable approach for minimizing peaks and troughs, but individual response varies significantly. A 2019 paper by Davis et al. in The Lancet Diabetes and Endocrinology found that optimal testosterone therapy in women requires individualized dosing and monitoring, not a one-size protocol.
Third, if you're on any form of testosterone therapy as a woman, you need regular serum labs, not symptom self-assessment guided by a spouse's observations about scratching. Testosterone therapy in women remains an area where monitoring matters precisely because the therapeutic window is narrow and supraphysiologic levels carry real risks including polycythemia and cardiovascular strain.
Her experience is valid as personal data. It's not a clinical comparison of delivery methods. Those are different things, and conflating them on a platform with 12,700 viewers has consequences.